Recent Investment Analysts’ Ratings Updates for Cryoport (CYRX)

Several brokerages have updated their recommendations and price targets on shares of Cryoport (NASDAQ: CYRX) in the last few weeks:

• 8/7/2024 – Cryoport had its price target lowered by analysts at UBS Group AG from $17.00 to $7.00. They now have a “neutral” rating on the stock.
• 8/7/2024 – Cryoport was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $20.00.
• 8/7/2024 – Cryoport had its price target lowered by analysts at Needham & Company LLC from $18.00 to $11.00. They now have a “buy” rating on the stock.
• 7/31/2024 – Cryoport was upgraded by analysts at B. Riley from a “neutral” rating to a “buy” rating. They now have a $15.00 price target on the stock, down previously from $19.00.

Cryoport Stock Down 2.3 %

NASDAQ CYRX traded down $0.22 on Tuesday, reaching $9.17. The company had a trading volume of 804,619 shares, compared to its average volume of 623,379. The firm has a market capitalization of $451.69 million, a PE ratio of -3.71 and a beta of 1.59. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22. The firm has a 50-day moving average of $8.22 and a 200-day moving average of $12.84. Cryoport, Inc. has a 1 year low of $5.32 and a 1 year high of $20.10.

Cryoport (NASDAQ:CYRX) last released its earnings results on Tuesday, August 6th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($0.37) by ($1.25). The business had revenue of $57.60 million for the quarter, compared to analysts’ expectations of $57.65 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) earnings per share. On average, equities research analysts anticipate that Cryoport, Inc. will post -1.39 EPS for the current fiscal year.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 4,167 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.04, for a total transaction of $33,502.68. Following the sale, the director now directly owns 56,032 shares of the company’s stock, valued at approximately $450,497.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 6,167 shares of company stock valued at $50,903. Corporate insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On Cryoport

Large investors have recently added to or reduced their stakes in the stock. Comerica Bank increased its position in Cryoport by 73.0% in the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after buying an additional 1,469 shares during the period. Natixis Investment Managers International increased its holdings in shares of Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock valued at $70,000 after purchasing an additional 1,727 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Cryoport by 294.3% during the first quarter. Lazard Asset Management LLC now owns 5,378 shares of the company’s stock valued at $95,000 after purchasing an additional 4,014 shares during the period. Quest Partners LLC increased its holdings in shares of Cryoport by 1,083,000.0% during the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in shares of Cryoport during the second quarter valued at $92,000. 92.90% of the stock is owned by institutional investors and hedge funds.

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.